Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonapanitase - Proteon Therapeutics

Drug Profile

Vonapanitase - Proteon Therapeutics

Alternative Names: PRT 201; Recombinant-human-type-I-pancreatic-elastase

Latest Information Update: 07 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 02 May 2019 Proteon Therapeutics withdraws a phase I trial in Peripheral arterial disorders in USA (NCT02953496)
  • 30 Apr 2019 Proteon Therapeutics completes a phase I trial in Peripheral arterial disorders in USA (NCT02956993)
  • 28 Mar 2019 Top-line efficacy and adverse events data from the phase III PATENCY-2 trial in Vascular disorders released by Proteon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top